Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
Name
s41467-017-01593-2.pdf
Size
1.84 MB
Format
Adobe PDF
Checksum (MD5)
4b18a6bef7ab750d2e27a4a38f01fa70
Author(s)
Cetin, Arif Engin
Stevens, Mark M.
Calistri, Nicholas L
Olcum, Selim A.
Kimmerling, Robert John
Manalis, Scott R
Date Issued
November 2017
Journal
Nature Communications
Publisher
Nature Publishing Group
Citation
Cetin, Arif E. et al. “Determining Therapeutic Susceptibility in Multiple Myeloma by Single-Cell Mass Accumulation.” Nature Communications 8, 1 (November 2017): 1613 © 2017 The Author(s)
Version
Final published version
Abstract
Multiple myeloma (MM) has benefited from significant advancements in treatment that have improved outcomes and reduced morbidity. However, the disease remains incurable and is characterized by high rates of drug resistance and relapse. Consequently, methods to select the most efficacious therapy are of great interest. Here we utilize a functional assay to assess the ex vivo drug sensitivity of single multiple myeloma cells based on measuring their mass accumulation rate (MAR). We show that MAR accurately and rapidly defines therapeutic susceptibility across human multiple myeloma cell lines to a gamut of standard-of-care therapies. Finally, we demonstrate that our MAR assay, without the need for extended culture ex vivo, correctly defines the response of nine patients to standard-of-care drugs according to their clinical diagnoses. This data highlights the MAR assay in both research and clinical applications as a promising tool for predicting therapeutic response using clinical samples.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution 4.0 International
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/s41467-017-01593-2
